Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243593 | 0.91 | DGAT1 (0.37) | SIGMAR1PRMT5DGAT1SCN5ASCN9A | |
| SCHEMBL6127063 | 0.87 | DGAT1 (0.34) | SIGMAR1DGAT1 | |
| SCHEMBL19075441 | 0.86 | SIGMAR1 (0.44) | SIGMAR1PRMT5DGAT1LRRK2 | |
| SCHEMBL6127068 | 0.86 | JAK2 (0.35) | SIGMAR1DGAT1KITLRRK2 | |
| SCHEMBL17220532 | 0.86 | DGAT1 (0.33) | SIGMAR1PRMT5DGAT1 | |
| SCHEMBL17220533 | 0.86 | DGAT1 (0.33) | SIGMAR1DGAT1LRRK2TBK1 | |
| SCHEMBL100799 | 0.85 | DGAT1 (0.35) | SIGMAR1DGAT1 | |
| SCHEMBL2383469 | 0.85 | JAK2 (0.38) | SIGMAR1DGAT1KITLRRK2 | |
| SCHEMBL19075431 | 0.84 | JAK2 (0.38) | DGAT1 | |
| SCHEMBL17466918 | 0.84 | DGAT1 (0.38) | DGAT1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463667-B2 | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE INCORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170326144-A1 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326144-A1 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | JAK2, JAK3, JAK1 | SIGMAR1 4305/4885PRMT5 303/4885DGAT1 2356/4885 |
| US-10463667-B2 | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | JAK3, JAK1, JAK2 | SIGMAR1 4138/4885PRMT5 276/4885DGAT1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.